SBIR/STTR Research Award

Development of a discovery platform based on microfluidics and fluorescent cell f

Award identifier 55029e726fe9f9214ce4d8b994ecd64a11142118217ea43733093271e5de06dfAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$695,816

Program and phase

SBIR · Phase I

Award year

2011

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NIVARTA, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PA08-114
Topic code
NIDDK

Research abstract

DESCRIPTION (provided by applicant): The overall goal of the project is to develop discovery platform based on microfluidics and functional cell assays that is suitable for screening hundreds of proteins or small-molecule compounds simultaneously in a cost-effective and high throughput manner. The projects Specific Aims are: (1) To develop a microfluidic-based platform for high-throughput screening of potential protein and small molecule therapeutics. (2) To develop an insulin stimulated glucose uptake assay in differentiated 3T3-L1 adipocytes using fluorescent 2-deoxy glucose (2-DOG) analog. (3) To integrate and perform a functional 2-DOG uptake assay in the microfluidics based multi-well cell culture biochip. The deliverable from this completed project isa cost-effective microfluidics based platform suitable for high throughput screening of proteins and small molecule therapeutic compounds. PUBLIC HEALTH RELEVANCE: The long term objective of the project is to identify protein and small molecule therapeutics to treat diseases such as diabetes, obesity, cancer and neurological disorders. As a first step towards this objective, a platform based on microfluidics technology and functional cell bioassays is being developed to screen the entire human proteome and small molecule libraries in a cost-effective and time saving manner. Presently, safety and efficacy of most of the drugs in the market is still a primary concern. However, with more therapies becoming available, it is possible that not only safety standards will be met but also the cost of drugs will be lowered.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.